Bioresorbable polymer coated drug eluting stent: a model study.
暂无分享,去创建一个
Giuseppe Perale | Maurizio Masi | Filippo Rossi | Tommaso Casalini | Edoardo Raffa | G. Perale | T. Casalini | F. Rossi | M. Masi | E. Raffa
[1] W L Hunter,et al. Solid-state characterization of paclitaxel. , 1997, Journal of pharmaceutical sciences.
[2] S. Venkatraman,et al. Paclitaxel release from single and double-layered poly(DL-lactide-co-glycolide)/poly(L-lactide) film for biodegradable coronary stent application. , 2008, Journal of biomedical materials research. Part A.
[3] J Wouter Jukema,et al. Drug-eluting stents: results, promises and problems. , 2005, International journal of cardiology.
[4] Suncica Canic,et al. Mathematical Modeling of Vascular Stents * , 2010 .
[5] F. Alexis. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)] , 2005 .
[6] Elazer R Edelman,et al. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[7] Caitríona Lally,et al. Determination of the influence of stent strut thickness using the finite element method: implications for vascular injury and in-stent restenosis , 2009, Medical & Biological Engineering & Computing.
[8] P. Zunino,et al. A Numerical Study of the Interaction of Blood Flow and Drug Release from Cardiovascular Stents , 2008 .
[9] G. Golomb,et al. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[10] F. Tondato,et al. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries. , 2006, The Journal of invasive cardiology.
[11] Patrick W Serruys,et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.
[12] Suming Li,et al. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. , 1995, Biomaterials.
[13] T. Fojo,et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity , 2001, Oncogene.
[14] E. Duek,et al. Use of triethylcitrate plasticizer in the production of poly-L-lactic acid implants with different degradation times , 2003, Journal of materials science. Materials in medicine.
[15] M. Fillinger,et al. Effect of endothelial cells and transforming growth factor-beta 1 on cultured vascular smooth muscle cell growth patterns. , 1994, Journal of vascular surgery.
[16] V. Busini,et al. Mechanistic modelling of avascular tumor growth and pharmacokinetics influence—Part I , 2007 .
[17] Mary E. Russell,et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005 .
[18] H. Burt,et al. Drug-eluting stents: factors governing local pharmacokinetics. , 2006, Advanced drug delivery reviews.
[19] B. Tesfamariam. Drug Release Kinetics From Stent Device-Based Delivery Systems , 2008, Journal of cardiovascular pharmacology.
[20] New Frontiers in Cardiology Drug-Eluting Stents: Part II Clinical Cardiology: New Frontiers , 2022 .
[21] Michel Vert,et al. Biodegradable polymers and plastics , 1992 .
[22] M. Böhm,et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. , 2003, Journal of the American College of Cardiology.
[23] Patrick W Serruys,et al. New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.
[24] S. Yalkowsky,et al. Solubilization of rapamycin. , 2001, International journal of pharmaceutics.
[25] H. Tsuji,et al. Alkaline and enzymatic degradation of L‐lactide copolymers. II. Crystallized films of poly(L‐lactide‐co‐D‐lactide) and poly(L‐lactide) with similar crystallinities , 2005 .
[26] G. Golomb,et al. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[27] Chad Johnson,et al. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. , 2004, Biomaterials.
[28] Ruediger C. Braun-Dullaeus,et al. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies , 2002, Nature Medicine.
[29] Luca Formaggia,et al. MODELING POLYMERIC CONTROLLED DRUG RELEASE AND TRANSPORT PHENOMENA IN THE ARTERIAL TISSUE , 2010 .
[30] G. Perale,et al. A new model of resorbable device degradation and drug release: transient 1-dimension diffusional model. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[31] Sanjay Pant,et al. Geometry parameterization and multidisciplinary constrained optimization of coronary stents , 2011, Biomechanics and Modeling in Mechanobiology.
[32] L. Buellesfeld,et al. BioMatrix® Biolimus A9®-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease , 2006, Expert review of medical devices.
[33] Kumbakonam R. Rajagopal,et al. Modeling the response of nonlinear viscoelastic biodegradable polymeric stents , 2012 .
[34] A. Göpferich,et al. Why degradable polymers undergo surface erosion or bulk erosion. , 2002, Biomaterials.
[35] G Dubini,et al. Modelling drug elution from stents: effects of reversible binding in the vascular wall and degradable polymeric matrix , 2008, Computer methods in biomechanics and biomedical engineering.
[36] J. Parikh,et al. Mechanism and in Vitro Release Kinetic Study of Sirolimus from a Biodegradable Polymeric Matrix Coated Cardiovascular Stent , 2011 .
[37] S. Hossainy,et al. A theoretical model to characterize the drug release behavior of drug-eluting stents with durable polymer matrix coating. , 2012, Journal of biomedical materials research. Part A.
[38] CHRISTIAN VERGARA,et al. Multiscale Boundary Conditions for Drug Release from Cardiovascular Stents , 2008, Multiscale Model. Simul..
[39] G. Perale,et al. Drug eluting sutures: a model for in vivo estimations. , 2012, International journal of pharmaceutics.
[40] E. Edelman,et al. Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits , 2003, Circulation.
[41] S. Hossainy,et al. Modeling of degradation and drug release from a biodegradable stent coating. , 2007, Journal of biomedical materials research. Part A.
[42] X. Zhu,et al. Physical models of diffusion for polymer solutions, gels and solids , 1999 .
[43] Suming Li,et al. Enzymatic degradation of block copolymers obtained by sequential ring opening polymerization of l-lactide and ɛ-caprolactone , 2007 .
[44] B. Xu,et al. In vitro and in vivo changes to PLGA/sirolimus coating on drug eluting stents. , 2010, Biomaterials.
[45] S. Hossainy,et al. A mathematical model for predicting drug release from a biodurable drug-eluting stent coating. , 2008, Journal of biomedical materials research. Part A.
[46] L. Khachigian,et al. Recent developments in drug-eluting stents , 2011, Journal of Molecular Medicine.
[47] J. Davies,et al. In vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam. , 1999, Biomaterials.
[48] Giuseppe Perale,et al. A new model of resorbable device degradation and drug release - part I: zero order model , 2008 .
[49] G. Golomb,et al. Route of administration-dependent anti-inflammatory effect of liposomal alendronate. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[50] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.
[51] J. Liao,et al. Inhibition of Vascular Smooth Muscle Cell Proliferation by Sodium Salicylate Mediated by Upregulation of p21Waf1 and p27Kip1 , 2000, Circulation.
[52] S. Hill,et al. Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry. , 1998, Rapid communications in mass spectrometry : RCM.
[53] Francesco Migliavacca,et al. Model Reduction Strategies Enable Computational Analysis of Controlled Drug Release from Cardiovascular Stents , 2011, SIAM J. Appl. Math..
[54] K. Na,et al. An acetylated polysaccharide-PTFE membrane-covered stent for the delivery of gemcitabine for treatment of gastrointestinal cancer and related stenosis. , 2011, Biomaterials.
[55] Brad S. Hubbard,et al. In Vitro and In Vivo Characterization of Novel Biodegradable Polymers for Application as Drug-Eluting Stent Coatings , 2010, Journal of biomaterials science. Polymer edition.
[56] David Martin,et al. Computational structural modelling of coronary stent deployment: a review , 2011, Computer methods in biomechanics and biomedical engineering.
[57] A. Mikos,et al. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. , 1999, Journal of biomedical materials research.
[58] H. Tsuji,et al. Alkaline and enzymatic degradation of L-lactide copolymers, 1. Amorphous-made films of L-lactide copolymers with D-lactide, glycolide, and epsilon-caprolactone. , 2005, Macromolecular bioscience.
[59] Gregg W Stone,et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.
[60] Gerhard A. Holzapfel,et al. A Numerical Model to Study the Interaction of Vascular Stents with Human Atherosclerotic Lesions , 2007, Annals of Biomedical Engineering.
[61] Y. Weng,et al. Preparation and characterization of rapamycin-loaded PLGA coating stent , 2007, Journal of materials science. Materials in medicine.
[62] E. Edelman,et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[63] J. S. Vrentas,et al. Diffusion in glassy polymers , 2003 .
[64] H. Kroemer,et al. Examination of drug release and distribution from drug-eluting stents with a vessel-simulating flow-through cell. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[65] A. Tzafriri,et al. Luminal flow patterns dictate arterial drug deposition in stent-based delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[66] R. Falotico,et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. , 2005, European journal of pharmacology.
[67] A. Göpferich,et al. Mechanisms of polymer degradation and erosion. , 1996, Biomaterials.
[68] Lei Lei,et al. Stents as a platform for drug delivery , 2011, Expert opinion on drug delivery.
[69] Francesco Migliavacca,et al. Hemodynamics and In-stent Restenosis: Micro-CT Images, Histology, and Computer Simulations , 2011, Annals of Biomedical Engineering.
[70] Kinam Park,et al. Mechanisms of controlled drug release from drug-eluting stents. , 2006, Advanced drug delivery reviews.
[71] Dimitris Karnabatidis,et al. Computational representation and hemodynamic characterization of in vivo acquired severe stenotic renal artery geometries using turbulence modeling. , 2008, Medical engineering & physics.
[72] A. Kastrati,et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. , 2010, Journal of the American College of Cardiology.
[73] F. Boey,et al. Release profiles in drug-eluting stents: issues and uncertainties. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[74] R. Virmani,et al. Drug-eluting stents: caution and concerns for long-term outcome , 2004, Coronary artery disease.
[75] S. Venkatraman,et al. Adjustable paclitaxel release kinetics and its efficacy to inhibit smooth muscle cells proliferation. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[76] E. Edelman,et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. , 2000, Journal of the American College of Cardiology.
[77] B. Buchholz,et al. In vitro and in vivo degradation of poly(D, L-lactide-co-glycolide)/amorphous calcium phosphate copolymer coated on metal stents. , 2011, Journal of biomedical materials research. Part A.
[78] H. Uehata,et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.
[79] L. P. Tan,et al. Effect of plasticization on heparin release from biodegradable matrices. , 2004, International journal of pharmaceutics.
[80] Jong-Chul Park,et al. Underlying mechanism for suppression of vascular smooth muscle cells by green tea polyphenol EGCG released from biodegradable polymers for stent application. , 2010, Journal of biomedical materials research. Part A.
[81] A. Greiner,et al. Poly(ethylene carbonate): a thermoelastic and biodegradable biomaterial for drug eluting stent coatings? , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[82] A. Albertsson,et al. Enzymatic degradation of monolayer for poly(lactide) revealed by real-time atomic force microscopy: effects of stereochemical structure, molecular weight, and molecular branches on hydrolysis rates. , 2008, Biomacromolecules.